Insmed reported $-84649000 in EBITDA for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Acelrx Pharmaceuticals ACRX:US $ -9.1M 0.11M
Alexion Pharmaceuticals ALXN:US $ 892.3M 186.4M
Arena Pharmaceuticals ARNA:US $ -143.42M 12.4M
Biomarin Pharmaceutical BMRN:US $ 41.16M 14.24M
Cytokinetics CYTK:US $ -54.25M 14.18M
Dynavax Technologies DVAX:US $ 10.78M 19.34M
Flexion Therapeutics FLXN:US $ -16357000 6.26M
Gilead Sciences GILD:US $ 2816M 669M
Heron Therapeutics HRTX:US $ -59.74M 8.36M
Insmed INSM:US $ -84649000 4.74M
Mirati Therapeutics MRTX:US $ -163.78M 31.65M
Regeneron Pharmaceuticals REGN:US $ 3418.3M 2238.2M
Sarepta Therapeutics SRPT:US $ -159.13M 26.19M
Seattle Genetics SGEN:US $ -73.78M 33.35M
Ultragenyx Pharmaceutical RARE:US $ -79.66M 23.55M
Vertex Pharmaceuticals VRTX:US $ -5.12M 917.88M